Amicus Therapeutics has two products in the market that generated more than $528 million in revenue last year.

Amicus is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales in 2028. The Company anticipates continuing to grow its current commercial ...

Q4 2024 Earnings Call Transcript February 19, 2025 Amicus Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Wells Fargo analyst Tiago Fauth lowered the firm’s price target on Amicus (FOLD) to $17 from $18 and keeps an Overweight rating on the shares.

Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Thursday. A number of other ...

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.11 per share a year ago. These ...

Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.